i don't know the nature of the ADA meeting. but if it were an emergenyc medicine meeting and somebody presented from the company who makes a drug that hadn't been approved yet (and wasn't gonna be on the shelves or in the pyxis for over a year), i'd be kinda pissed that the conf wasted my time on it and so would many others. i can see a mention about it hear or there as something coming down the pike, but a podium presentation. i think i recall that mnkd has presented at either the ada or some other endocrine/academic conf in the past, but i wouldn't think twice about it not being in the line-up. if this were to happen next year however, that would be BAD news. as revolutionary as afrezza may be, it's still a speculative situation.